Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 5/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.61 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31473504 | 0.93 | CCR5 (0.56) | CCR5SIGMAR1PTGDR2EPHX2SMN1; SMN2 | |
| SCHEMBL11394433 | 0.93 | SIGMAR1 (0.64) | CCR5SIGMAR1PTGDR2EPHX2SMN1; SMN2 | |
| SCHEMBL5860907 | 0.90 | CCR5 (0.56) | CCR5SIGMAR1PTGDR2EPHX2SMN1; SMN2 | |
| SCHEMBL2406118 | 0.84 | CCR5 (0.61) | CCR5SIGMAR1PTGDR2ALDH1A1 | |
| SCHEMBL5862792 | 0.83 | KCNH2 (0.72) | CCR5SIGMAR1 | |
| SCHEMBL8987850 | 0.82 | CCR5 (0.54) | CCR5SIGMAR1PTGDR2EPHX2SMN1; SMN2 | |
| SCHEMBL2404203 | 0.82 | CCR5 (0.65) | CCR5SIGMAR1EPHX2 | |
| SCHEMBL2404816 | 0.82 | CCR5 (0.66) | CCR5SIGMAR1ALDH1A1 | |
| SCHEMBL2407533 | 0.82 | KCNH2 (0.49) | CCR5SIGMAR1 | |
| SCHEMBL2405156 | 0.82 | CCR5 (0.60) | CCR5SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | CCR5 2055/4885SIGMAR1 108/4885PTGDR2 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.